Allergy Relief D, Fexofenadine HCL 60mg/Antihistamine, Pseudoephedrine HCL 120mg/Nasal Decongesta...
FDA Drug Recall #D-0073-2023 — Class III — November 21, 2022
Recall Summary
| Recall Number | D-0073-2023 |
| Classification | Class III — Low risk |
| Date Initiated | November 21, 2022 |
| Status | Terminated |
| Voluntary | — |
Recalling Firm
| Firm | Dr. Reddy's Laboratories, Inc. |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 25,176, 30-count; 22,968 20-count |
Product Description
Allergy Relief D, Fexofenadine HCL 60mg/Antihistamine, Pseudoephedrine HCL 120mg/Nasal Decongestant, Extended-Release Tablets USP, packaged as (a) 20 count carton NDC 49032-273-20; (b) 30 count carton, NDC49032-273-30; Distributed by: Walmart Inc., Bentonville, AR 72716, Product of India
Reason for Recall
Failed dissolution specifications
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot# (a) AC2203133B, EXP 01/2024; (b) AC2203133A, EXP 01/2024.
Other Recalls from Dr. Reddy's Laboratories, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0219-2026 | Class III | Varenicline Tablets, 1mg, 56 Tablets, Rx only, ... | Nov 11, 2025 |
| D-0008-2026 | Class II | Succinylcholine Chloride Injection, USP, 200 mg... | Sep 26, 2025 |
| D-0525-2025 | Class II | Omeprazole Delayed-release Capsules, USP, 20mg,... | Jun 30, 2025 |
| D-0365-2025 | Class I | Levetiracetam 0.75% in Sodium Chloride Injectio... | Mar 13, 2025 |
| D-0117-2025 | Class III | Javygtor (sapropterin dihydrochloride) Tablets ... | Nov 22, 2024 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.